Conditions: Stroke, Acute Neurological Impairment
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 204
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the effectiveness of Tanakan® 240mg in association with Acetylsalicylic acid (325mg/day) in the recovery of neurological impairment following ischemic stroke.

Detailed description:

Arms:
arm 1: EGb761® 240 milligrams (mg)/day for 6 months administered orally, in association with acetylsalicylic acid (325 mg/day).

The test treatment consists of 6 tablets/day. 2 tablets (each containing 40 mg EGb761®) taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch. arm 2: 6 months, administered orally, in association with acetylsalicylic acid (325 mg/day).

The placebo consists of 6 tablets/day. 2 tablets taken orally with half a glass of water during 3 main meals. 1 tablet/day of acetylsalicylic acid during lunch.

Interventions: intervention 1: EGb761 intervention 2: Placebo intervention 3: Acetylsalicylic acid
Intervention descriptions: intervention 1: EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months. intervention 2: Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months. intervention 3: Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.

Protocol document: